Stock Taper
| DATE | TYPE | RATIO |
|---|---|---|
| 2026-02-06 | Reverse | 1:8 |
Rallybio is a clinical-stage biotech developing therapies for rare diseases, including monoclonal antibodies and complement inhibitors, with collaborations with AbCellera, Exscientia, and J&J.

RLYB116 is a C5 inhibitor developed by Rallybio to treat complement dysregulation diseases, now their leading and most advanced therapy after discontinuing their previous candidate.
| Icon | PRODUCT | Q2-2025 | Q3-2025 | Q4-2025 | Q1-2026 |
|---|---|---|---|---|---|
![]() | Collaboration And License Revenue | $212K | $212K | $222K ▲ | $212K ▼ |
Overall rating: A-
| PEER | PRICE | |
|---|---|---|
QTTB | $15.03 | COMPARE |
BOLD | $2.83 | COMPARE |
TAOX | $3.89 | COMPARE |
IBIO | $1.36 | COMPARE |
INTS | $4.25 | COMPARE |
XCUR | $1.29 | COMPARE |
CVKD | $1.54 | COMPARE |